Jul 24 |
Biogen, Sage discontinue neuro candidate after mid-stage setback
|
Jul 24 |
Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
|
Jul 23 |
Nanotechnology in medicine: Who are the leading public companies?
|
Jul 22 |
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
|
Jul 22 |
Ionis plots next steps for Angelman drug Biogen passed on
|
Jul 22 |
Sage Therapeutics/Biogen’s episodic therapy zuranolone could change MDD treatment
|
Jul 19 |
Ionis (IONS) Completes Enrolment for Rare Disease Drug Study
|
Jul 17 |
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
|
Jul 16 |
Three Surprising Names That Could Be On Biogen's Buyout Shortlist
|
Jul 16 |
Viridian, Pharvaris said to be among prime M&A targets for Biogen
|